Inventiva’s IVA337 Given Generic Name “Lanifibranor” by the World Health Organization (WHO)
Announces exercise of option by Boehringer Ingelheim to jointly develop potential new treatments for idiopathic pulmonary fibrosis (IPF)
Inventiva to present at the Jefferies HealthCare Conference, New-York, June 9th 2017
INVENTIVA: FIRST-HALF 2017 RESULTS
Announces the partial exercise of the over-allotment option
Inventiva raises €48 million in a successful initial public offering
Announces initiation of Phase IIb Clinical Trial of IVA337 in NASH
No front page content has been created yet.